A recent study has raised doubts about the long-term effectiveness of weight loss injections such as Wegovy and Mounjaro. These injections, previously praised for their significant impact on weight loss, have shown promising results in clinical trials, where participants achieved a weight reduction of 15%-20%, far surpassing results from conventional diet and exercise regimes.
However, new research has revealed a concerning trend post-medication cessation. The study indicates a rapid weight regain following the discontinuation of the injections, prompting scientists to question the sustainability of the treatment in the long run.
Notably, experts from the University of Oxford, including Sam West, Dimitrios Koutoukidis, and Susan Jebb, have analyzed these findings. Their evaluation suggests that prolonged use of the medication may pose financial challenges for individuals, raising doubts about its cost-effectiveness.
The study reveals that a significant portion of individuals in the UK, approximately 1 in 50, opt for these treatments, mainly through private means at a monthly expense ranging from £120 to £250. However, over half of the users discontinue the medication within a year, primarily due to cost constraints.
Furthermore, the research highlights that individuals tend to regain all the lost weight within just 18 months of stopping the injections, a rate much faster than observed with traditional weight loss methods involving diet and exercise. Additionally, health benefits gained during the treatment, such as improved blood pressure and cholesterol levels, revert to pre-treatment levels upon discontinuation.
The experts emphasize the necessity of potentially lifelong use of these medications to sustain the benefits, pointing out that additional support during or after the treatment does not significantly impact weight maintenance post-medication.
The rapid weight regain post-treatment cessation raises concerns about equity and the value proposition of these treatments within the healthcare system. Access to these medications through the NHS is limited to individuals with severe obesity and specific related conditions, while others must rely on private funding, which may not be sustainable for many.
The experts suggest that re-evaluating the cost-effectiveness of these medications outside of controlled trials is imperative. For individuals not meeting strict NHS criteria, alternative weight management programs, such as total diet replacement plans or group-based interventions like WW and Slimming World, may offer more cost-effective solutions compared to long-term medication use.
While the demand for weight loss interventions remains high, the sustainability and financial implications of long-term medication use raise significant uncertainties. Prioritizing accessible and cost-effective obesity treatment options could enhance public health outcomes and ensure equitable access to care for all individuals.